KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBITDA (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of EBITDA data on record, last reported at $151.1 million in Q4 2025.

  • For Q4 2025, EBITDA fell 51.66% year-over-year to $151.1 million; the TTM value through Dec 2025 reached $1.3 billion, down 8.3%, while the annual FY2025 figure was $1.3 billion, 8.3% down from the prior year.
  • EBITDA reached $151.1 million in Q4 2025 per EW's latest filing, down from $307.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $542.1 million in Q2 2021 and bottomed at $151.1 million in Q4 2025.
  • Average EBITDA over 5 years is $362.4 million, with a median of $379.0 million recorded in 2021.
  • Peak YoY movement for EBITDA: surged 419.45% in 2021, then plummeted 51.66% in 2025.
  • A 5-year view of EBITDA shows it stood at $374.4 million in 2021, then tumbled by 47.2% to $197.7 million in 2022, then soared by 75.42% to $346.8 million in 2023, then decreased by 9.86% to $312.6 million in 2024, then tumbled by 51.66% to $151.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $151.1 million in Q4 2025, $307.1 million in Q3 2025, and $411.2 million in Q2 2025.